You are not the patient. That is what makes this hard.
Someone you love has been through two or three antidepressants and is still flat, still not sleeping, still not themselves. You have read enough about ketamine and esketamine to wonder whether they belong on the list of things left to try. Now you are the one holding the phone, working out how a person reaches that door on behalf of someone who may lack the energy to do it.
There are two ways in. You can raise it with their regular doctor and ask for an evaluation and referral, or you can research clinics yourself and call one directly.
Our June 2026 survey asked 443 Midwest adults, drawn from ten states, whose recommendation would genuinely move them toward ketamine or esketamine therapy. Three in four, 74 percent, pointed to their own doctor. A close friend or relative would sway 18 percent and someone in uniform they follow online 4, while ads stalled at 2 percent and podcasters at 1. Those shares are final.
Read the second figure again, because it is you. In a category where advertising barely registers, the people closest to a patient are the second-strongest voice in the room, so you have more standing than you think. What you lack is the clinical authority that 74 percent of respondents are waiting on.
Route one: raise it with the doctor who already knows them
This is the route most people say they would take. For a first stop, the primary doctor drew 56 percent of respondents and psychiatry 23.
- What it asks of you: an appointment, a short written history of what has been tried and for how long, and patience to let a clinician reach their own conclusion.
- Where it stalls: familiarity. Spravato, an esketamine nasal spray cleared for hard-to-treat depression, was a new name to most of our respondents, 73 percent of them, and a general practice may not have the referral path at its fingertips. The ask that moves things is usually a psychiatric referral, not an on-the-spot decision.
- What it costs in time: weeks, sometimes more, for an appointment, a referral, a second appointment, and scheduling. It is the slower route on paper.
- What it does for coverage: this is where the time comes back. A record of the medications that failed is exactly what an insurer will ask for, and building it through the doctor first means you are not assembling it in a panic later.
Route two: find the clinic yourself and call
Searching the web alone was the plan for 12 percent of respondents, leaning on a friend for 1 percent, and 5 percent would be stuck from the outset.
- What it asks of you: judgment. No referral is filtering clinics for you, so ask each one direct questions and be willing to hang up.
- Where it stalls: the distinction no homepage explains. Spravato's approval is specific to treatment-resistant depression, and it is given in a certified setting, with a clinician supervising the dose and keeping the patient to be watched afterward. At-home ketamine through a telehealth service is a different and much grayer thing. Marketing will not always say which one you are being offered, so ask plainly and get an answer you can repeat back. Brain Recovery Centers' page on its Spravato treatment is one example of the clear description to look for.
- What it costs in time: less at the start, since a screening call often comes quickly. The delay usually moves rather than vanishes, landing later when records are requested or prior authorization is filed.
- What it does for coverage: this is the real risk. Among respondents, coverage outranked proximity 85 percent to 43 percent as a top-two provider factor. Whether to try the treatment at all would hinge on insurance for 22 percent, and another 43 percent rated insurance a big factor. A cash-pay clinic can start faster and still be the wrong first call for a family that cannot sustain it.
What the survey suggests people actually do
Most people in the survey would start with some kind of clinician, primary care at 56 percent or psychiatry at 23 percent, and only 12 percent with a search engine. Whichever route feels faster to you, the person you are helping will likely want a doctor's blessing before agreeing to anything, and pushing a clinic on someone without it tends to produce a polite no.
The clinician route is slower to start and harder to stop. The self-directed route is faster to start and much easier to stall out.
Running both at once
There is no need to choose. What seems to work best treats the two routes as one sequence.
- Book the primary care appointment first, even if you expect a referral rather than an answer. It starts the paper trail.
- While you wait, research with questions instead of enthusiasm: which nearby clinics are certified for esketamine, which insurers they contract with, and whether they need a psychiatric referral before an evaluation.
- Call the insurer before any clinic. Ask what is covered, what documentation is required, and whether prior authorization is needed, and note the date and the name of whoever answers.
- Bring what you learned into the appointment as information, not a request for a specific drug. A one-page list of medications, dates, and results is worth more than anything else you can hand a clinician.
- Let the patient speak for themselves wherever possible. Your job is logistics and persistence; theirs is the history only they can give.
What this data is and what it is not
This measures opinion and intent. It is not clinical evidence or medical advice. No treatment here is promised to help, and whether ketamine or esketamine suits the person you are helping is for a clinician who knows their full history and medications.
One more thing matters more than the logistics above. If the person you care for has started talking about not wanting to be here, or the weight on you has grown too heavy, 988 answers by phone or text around the clock, holidays included, and it helps family members as readily as the person struggling.
Methodology
The publisher commissioned and paid for survey 395586438, run on the Pollfish consumer panel with a June 23, 2026 close. Respondents numbered 443, adults from ten Midwest states aged 18 through 64. Multi-select questions are shares of respondents and run past 100. Each number comes from the validated panel.